Treatment preference and quality of life impact: ravulizumab vs eculizumab for atypical hemolytic uremic syndrome by Teri J Mauch, Michael R Chladek, Spero Cataland, Shruti Chaturvedi, Bradley P Dixon, Katherine Garlo, Anuja Java, Jorge Leguizamo, Lucy Lloyd-Price, Tan P Pham, Tara Symonds, Ioannis Tomazos, Yan Wang

Connect to this object online.